BioSpace News Archive

Combined Phase 1b/2 CARTITUDE-1 study presented at ASH 2020 Annual Meeting show 97 percent overall response rate and 12-month progression free survival rate of 77 percent at median follow up of 12.4 months

Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, announced an interim readout to evaluate the safety and efficacy of its potential first-in-class GC012F FasTCAR-enabled dual-targeting BCMA/CD19 cell therapy in patients with relapsed or refractory multiple myeloma.

Potentially registrational Phase 2 portion of the trial has been initiated and is enrolling patients

Oral presentation at 62nd ASH Annual Meeting and Exposition points to potential role for uproleselan as foundational therapy in acute myeloid leukemia (AML)

Lead immuno-oncology development candidate NTLA-5001shows high anti-tumor activity as promising cancer treatmentin proof-of-concept mouse models of acute leukemias

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that preclinical data with FTX-6058 for the treatment of sickle cell disease will be presented in three posters at the virtual 62nd American Society of Hematology Annual Meeting and Exposition taking place December 5-8, 2020.

Significant and Durable Rate of Complete Response Further Supports Tecartus as First and Only CAR T-Cell Therapy in Relapsed or Refractory MCL

Rhizen announces presentation of interim data from its Tenalisib + Romidepsin combination study in patients with relapsed/refractory peripheral and cutaneous T cell lymphoma.

Momelotinib demonstrates robust overall survival in both JAKi-naïve and patients previously treated with ruxolitinib

New studies seek to identify patients most vulnerable to severe COVID-19 illness, develop off-the-shelf treatments to boost immune responses for some patients